Don't miss: Sunday, March 24th, 6:30 - 7:30pm Henry B. González Convention Center, Room 214D The Antibody Crisis: Leveraging machine learning for evidence-based antibody search Monday, March 25, 4:30 - 5:30 Room 214ABC Rigor and Reproducibility Practices in a Core Setting Featuring: Kevin Knudston, Susan Meyn, Ian Sullivan, Stephen Uebel
Posts in Core Rigor and Reproducibility (CoRRe)
Poorly validated antibodies and inadequate documentation in manuscripts play a role in the irreproducibility of scientific advancements. In this webinar, we will provide an overview of the role antibodies play in irreproducible experiments, general antibody validation practices and review online search engines established to assist researchers in choosing antibodies that have a good chance of meeting their scientific needs. One of the search engines is an open-access resource that uses a machine learning algorithm to screen the literature and search the peer-reviewed data by protein targets or product identifier, and are filterable by experimental contexts as cited in papers, including technique, tissue, cell line, to help users pinpoint antibodies that have been published under experimental conditions matching their study interest. Speaker: Maurice Shen, PhD. Head of Academic Relations, BenchSci Date: Monday, January 14, 2019 Time: 11 am – 12 pm EST Webinar: Register at http://evt.to/euduemhw. Invitations will go out 5 pm EST this Friday, January 11th. If you have any question or do not get an invitation by Saturday, email Frances at <email obscured>.
Hi, Below is a link to a webinar (sponsored by the ABRF) presented by University of Colorado BioFrontiers Institute on how they work with core facilities to bring computing best practices into their workflows. https://us1.campaign-archive.com/?u=0ee9670bb3fd42d46d0fa9631&id=6357d87312&e=9ac8f44798
Thanks, Kevin -- Kevin L. Knudtson, Ph.D. University of Iowa Director, IIHG Genomics Division 116B EMRB Iowa City, IA 52242
FASEB announced a new webinar on Tuesday Sept 11 from 2-3 PM EDT. Title: Enhancing Research Rigor and Reproducibility Register here: https://register.gotowebinar.com/register/827784214547765507
Glad to know this is of interest to you too Laura. You can link to each chapter meeting at the bottom of the ABRF website. https://abrf.org/ The on in Atlanta (SEASR 2018) is focusing on R&R too and is at the end of June. http://seasr.abrf.org/ The one the fall do not have themes yet. -----Original Message----- From: "Core Rigor and Reproducibility (CoRRe)" <email obscured>> on behalf of Laura Bover <email obscured>> Reply-To: <email obscured>> Date: Tuesday, May 29, 2018 at 12:56 PM To: <email obscured>" <email obscured>> Cc: Laura Bover <email obscured>> Subject: Re: [core rigor and reproducibility (corre)] Guidelines for antibody validation in research settings Citing you Frances, “I wish I had the time as I think a nice summary of efforts around this topic, ideally finding common points of action, would be a nice JBT article. I also dream of working with other ABRFers to help push this culture shift forward. So much to do. So little time.” I wish the same. And I can try hard to find the time. May be dividing the duties, the job can be done. Count on me if you find your minutes. Thanks! Laura BTW, I was trying to accommodate my schedule to attend the MADSSC 2018 meeting but I cannot move things around. I don’t find the mail you sent me about another conference in Atlanta that will talk about the Rigor. Don’t even remember the date to see if I can attend that one. Could you please send it again? Thanks! Laura Bover, PhD Professor Director Monoclonal Antibody Core Facility University of Texas M.D.Anderson Cancer Center Associate member of The University of Texas Graduate School of Biomedical Sciences at Houston Immunology Department/ Genomics Medicine Department 7455 Fannin St Room 1SCR4.3015/ 1901 East Rd- Room 4SCR5.1039 Houston- TX 77054 T 713-563-2281/ 713-563-3301 F 713-563-3276 <email obscured> <email obscured>> On 5/3/18, 10:59 AM, "Core Rigor and Reproducibility (CoRRe) on behalf of Frances Weis-Garcia" <email obscured> on behalf of <email obscured>> wrote: For those interested on this topic ... I came across a paper by EuroMAbNet (https://www.euromabnet.com/about-us/) describing guidelines for validating antibodies. Guidelines Website: https://www.euromabnet.com/guidelines/index.php Guidelines Manuscript: https://www.ncbi.nlm.nih.gov/pubmed/26418356 Pos/Neg Controls Website: https://www.euromabnet.com/guidelines/positive-negative-controls.php Additional Articles about Ab Validation on their website: https://www.euromabnet.com/guidelines/articles-about-antibody-validation.php I wish I had the time as I think a nice summary of efforts around this topic, ideally finding common points of action, would be a nice JBT article. I also dream of working with other ABRFers to help push this culture shift forward. So much to do. So little time. ―― View topic http://list.abrf.org/r/topic/5dDocqgZV31zHKnxcs4H3n Leave group <email obscured>?Subject=Unsubscribe The information contained in this e-mail message may be privileged, confidential, and/or protected from disclosure. This e-mail message may contain protected health information (PHI); dissemination of PHI should comply with applicable federal and state laws. If you are not the intended recipient, or an authorized representative of the intended recipient, any further review, disclosure, use, dissemination, distribution, or copying of this message or any attachment (or the information contained therein) is strictly prohibited. If you think that you have received this e-mail message in error, please notify the sender by return e-mail and delete all references to it and its contents from your systems. ―― View topic http://list.abrf.org/r/topic/7teTVIDnWFBe1WMDxGWa8A Leave group <email obscured>?Subject=Unsubscribe
Citing you Frances,
“I wish I had the time as I think a nice summary of efforts around this topic,
ideally finding common points of action, would be a nice JBT article. I also
dream of working with other ABRFers to help push this culture shift forward.
So much to do. So little time.”
I wish the same. And I can try hard to find the time. May be dividing the
duties, the job can be done.
Count on me if you find your minutes.
Thanks!
Laura
BTW, I was trying to accommodate my schedule to attend the MADSSC 2018 meeting
but I cannot move things around. I don’t find the mail you sent me about
another conference in Atlanta that will talk about the Rigor. Don’t even
remember the date to see if I can attend that one.
Could you please send it again?
Thanks!
Laura Bover, PhD
Professor
Director Monoclonal Antibody Core Facility
University of Texas M.D.Anderson Cancer Center
Associate member of The University of Texas Graduate School of Biomedical
Sciences at Houston
Immunology Department/ Genomics Medicine Department
7455 Fannin St Room 1SCR4.3015/ 1901 East Rd- Room 4SCR5.1039
Houston- TX 77054
T 713-563-2281/ 713-563-3301
F 713-563-3276
<email obscured>
<email obscured>>
On 5/3/18, 10:59 AM, "Core Rigor and Reproducibility (CoRRe) on behalf of
Frances Weis-Garcia" <email obscured> on behalf of
<email obscured>> wrote:
For those interested on this topic ...
I came across a paper by EuroMAbNet (https://www.euromabnet.com/about-us/)
describing guidelines for validating antibodies.
Guidelines Website:
https://www.euromabnet.com/guidelines/index.php
Guidelines Manuscript:
https://www.ncbi.nlm.nih.gov/pubmed/26418356
Pos/Neg Controls Website:
https://www.euromabnet.com/guidelines/positive-negative-controls.php
Additional Articles about Ab Validation on their website:
https://www.euromabnet.com/guidelines/articles-about-antibody-validation.php
I wish I had the time as I think a nice summary of efforts around this
topic, ideally finding common points of action, would be a nice JBT article. I
also dream of working with other ABRFers to help push this culture shift
forward. So much to do. So little time.
――
View topic http://list.abrf.org/r/topic/5dDocqgZV31zHKnxcs4H3n
Leave group <email obscured>?Subject=Unsubscribe
The information contained in this e-mail message may be privileged,
confidential, and/or protected from disclosure. This e-mail message may contain
protected health information (PHI); dissemination of PHI should comply with
applicable federal and state laws. If you are not the intended recipient, or an
authorized representative of the intended recipient, any further review,
disclosure, use, dissemination, distribution, or copying of this message or any
attachment (or the information contained therein) is strictly prohibited. If
you think that you have received this e-mail message in error, please notify
the sender by return e-mail and delete all references to it and its contents
from your systems.
For those who cannot make the June 18-20 MADSSCi, SEASR is also focusing their meeting this spring on Rigor and Reproducibility, June 27-29, 2018 in Atlanta: http://seasr.abrf.org/
For those interested on this topic ... I came across a paper by EuroMAbNet (https://www.euromabnet.com/about-us/) describing guidelines for validating antibodies. Guidelines Website: https://www.euromabnet.com/guidelines/index.php Guidelines Manuscript: https://www.ncbi.nlm.nih.gov/pubmed/26418356 Pos/Neg Controls Website: https://www.euromabnet.com/guidelines/positive-negative-controls.php Additional Articles about Ab Validation on their website: https://www.euromabnet.com/guidelines/articles-about-antibody-validation.php I wish I had the time as I think a nice summary of efforts around this topic, ideally finding common points of action, would be a nice JBT article. I also dream of working with other ABRFers to help push this culture shift forward. So much to do. So little time.
Yes, I will be interested. I need to see the program.
I will also try to go but this is more difficult yet.
I have to go back to the lab and reorganize calendar.
Thanks Frances.
Laura Bover, PhD
Professor
Director Monoclonal Antibody Core Facility
University of Texas M.D.Anderson Cancer Center
Associate member of The University of Texas Graduate School of Biomedical
Sciences at Houston
Immunology Department/ Genomics Medicine Department
7455 Fannin St Room 1SCR4.3015/ 1901 East Rd- Room 4SCR5.1039
Houston- TX 77054
T 713-563-2281/ 713-563-3301
F 713-563-3276
<email obscured>
<email obscured>>
On 5/1/18, 12:47 PM, "Core Rigor and Reproducibility (CoRRe) on behalf of
Weis-Garcia, Frances/Sloan Kettering Institute" <email obscured> on behalf
of <email obscured>> wrote:
Doubt they will be recorded, but those going can pick out one or 2 that we
can likely repeat on a webcast. Any in which you are particularly interested?
F
-----Original Message-----
From: "Core Rigor and Reproducibility (CoRRe)" <email obscured>> on
behalf of Laura Bover <email obscured>>
Reply-To: <email obscured>>
Date: Tuesday, May 1, 2018 at 9:11 AM
To: <email obscured>" <email obscured>>
Subject: Re: [core rigor and reproducibility (corre)] Rigor and
Reproducibility at MADSSCi in June
Thanks for the info. It is a really important topic. Though, like
Frances said, I am not sure that I can attend. Will it be possible to record
the sessions and discussions or webcast?
Thanks
Laura Bover, PhD
Professor
Director Monoclonal Antibody Core Facility
University of Texas M.D.Anderson Cancer Center
Associate member of The University of Texas Graduate School of
Biomedical Sciences at Houston
Immunology Department/ Genomics Medicine Department
7455 Fannin St<x-apple-data-detectors://17/1> Room 1SCR4.3015/ 1901
East Rd- Room<x-apple-data-detectors://18>4SCR5.1039
Houston- TX 77054<x-apple-data-detectors://19/0>
T 713-563-2281<tel:713-563-2281>/ 713-563-3301<tel:713-563-3301>
F 713-563-3276<tel:713-563-3276>
<email obscured><email obscured>>
Sent from my iPhone
On May 1, 2018, at 9:16 AM, Weis-Garcia, Frances/Sloan Kettering
Institute
<email obscured><email obscured>>>
wrote:
Thanks for bringing this to our attention.
Sorry I cannot be there ... to much travel going on this spring / early
summer. Would love to know how it goes.
Frances
-----Original Message-----
From: "Core Rigor and Reproducibility (CoRRe)"
<email obscured><email obscured>>> on behalf of ncfisher
<email obscured><email obscured>>>
Reply-To: <email obscured><email obscured>>>
Date: Tuesday, May 1, 2018 at 8:04 AM
To: <email obscured><email obscured>>>
Subject: [core rigor and reproducibility (corre)] Rigor and
Reproducibility at MADSSCi in June
This year, the MADSSCi meeting in Baltimore will be dedicated to
Rigor and Reproducibility.
http://madssci.abrf.org/
Cores: At the Forefront of Rigor and Reproducibility
MAD SSCi 2018 Baltimore, MD - June 18-20, 2018
hosted by the Johns Hopkins University School of Medicine
Turner Building Concourse, 720 Rutland Avenue
――
View topic http://list.abrf.org/r/topic/3WaDbHyjr6Itqt7U34559u
Leave group <email obscured>?Subject=Unsubscribe
――
View topic http://list.abrf.org/r/topic/3ZhXRGsC24hwHVLCZdamOZ
Leave group <email obscured>?Subject=Unsubscribe
The information contained in this e-mail message may be privileged,
confidential, and/or protected from disclosure. This e-mail message may contain
protected health information (PHI); dissemination of PHI should comply with
applicable federal and state laws. If you are not the intended recipient, or an
authorized representative of the intended recipient, any further review,
disclosure, use, dissemination, distribution, or copying of this message or any
attachment (or the information contained therein) is strictly prohibited. If
you think that you have received this e-mail message in error, please notify
the sender by return e-mail and delete all references to it and its contents
from your systems.
――
View topic http://list.abrf.org/r/topic/6ddPluDXEUjslOjcv5YUqv
Leave group <email obscured>?Subject=Unsubscribe
――
View topic http://list.abrf.org/r/topic/IZZ42CHDZDl1d8kZI5Rnl
Leave group <email obscured>?Subject=Unsubscribe
The information contained in this e-mail message may be privileged,
confidential, and/or protected from disclosure. This e-mail message may contain
protected health information (PHI); dissemination of PHI should comply with
applicable federal and state laws. If you are not the intended recipient, or an
authorized representative of the intended recipient, any further review,
disclosure, use, dissemination, distribution, or copying of this message or any
attachment (or the information contained therein) is strictly prohibited. If
you think that you have received this e-mail message in error, please notify
the sender by return e-mail and delete all references to it and its contents
from your systems.
Doubt they will be recorded, but those going can pick out one or 2 that we can
likely repeat on a webcast. Any in which you are particularly interested?
F
-----Original Message-----
From: "Core Rigor and Reproducibility (CoRRe)" <email obscured>> on behalf
of Laura Bover <email obscured>>
Reply-To: <email obscured>>
Date: Tuesday, May 1, 2018 at 9:11 AM
To: <email obscured>" <email obscured>>
Subject: Re: [core rigor and reproducibility (corre)] Rigor and Reproducibility
at MADSSCi in June
Thanks for the info. It is a really important topic. Though, like Frances
said, I am not sure that I can attend. Will it be possible to record the
sessions and discussions or webcast?
Thanks
Laura Bover, PhD
Professor
Director Monoclonal Antibody Core Facility
University of Texas M.D.Anderson Cancer Center
Associate member of The University of Texas Graduate School of Biomedical
Sciences at Houston
Immunology Department/ Genomics Medicine Department
7455 Fannin St<x-apple-data-detectors://17/1> Room 1SCR4.3015/ 1901 East
Rd- Room<x-apple-data-detectors://18>4SCR5.1039
Houston- TX 77054<x-apple-data-detectors://19/0>
T 713-563-2281<tel:713-563-2281>/ 713-563-3301<tel:713-563-3301>
F 713-563-3276<tel:713-563-3276>
<email obscured><email obscured>>
Sent from my iPhone
On May 1, 2018, at 9:16 AM, Weis-Garcia, Frances/Sloan Kettering Institute
<email obscured><email obscured>>>
wrote:
Thanks for bringing this to our attention.
Sorry I cannot be there ... to much travel going on this spring / early
summer. Would love to know how it goes.
Frances
-----Original Message-----
From: "Core Rigor and Reproducibility (CoRRe)"
<email obscured><email obscured>>> on behalf of ncfisher
<email obscured><email obscured>>>
Reply-To: <email obscured><email obscured>>>
Date: Tuesday, May 1, 2018 at 8:04 AM
To: <email obscured><email obscured>>>
Subject: [core rigor and reproducibility (corre)] Rigor and Reproducibility
at MADSSCi in June
This year, the MADSSCi meeting in Baltimore will be dedicated to Rigor
and Reproducibility.
http://madssci.abrf.org/
Cores: At the Forefront of Rigor and Reproducibility
MAD SSCi 2018 Baltimore, MD - June 18-20, 2018
hosted by the Johns Hopkins University School of Medicine
Turner Building Concourse, 720 Rutland Avenue
――
View topic http://list.abrf.org/r/topic/3WaDbHyjr6Itqt7U34559u
Leave group <email obscured>?Subject=Unsubscribe
――
View topic http://list.abrf.org/r/topic/3ZhXRGsC24hwHVLCZdamOZ
Leave group <email obscured>?Subject=Unsubscribe
The information contained in this e-mail message may be privileged,
confidential, and/or protected from disclosure. This e-mail message may contain
protected health information (PHI); dissemination of PHI should comply with
applicable federal and state laws. If you are not the intended recipient, or an
authorized representative of the intended recipient, any further review,
disclosure, use, dissemination, distribution, or copying of this message or any
attachment (or the information contained therein) is strictly prohibited. If
you think that you have received this e-mail message in error, please notify
the sender by return e-mail and delete all references to it and its contents
from your systems.
――
View topic http://list.abrf.org/r/topic/6ddPluDXEUjslOjcv5YUqv
Leave group <email obscured>?Subject=Unsubscribe
Thanks for the info. It is a really important topic. Though, like Frances said, I am not sure that I can attend. Will it be possible to record the sessions and discussions or webcast? Thanks Laura Bover, PhD Professor Director Monoclonal Antibody Core Facility University of Texas M.D.Anderson Cancer Center Associate member of The University of Texas Graduate School of Biomedical Sciences at Houston Immunology Department/ Genomics Medicine Department 7455 Fannin St<x-apple-data-detectors://17/1> Room 1SCR4.3015/ 1901 East Rd- Room<x-apple-data-detectors://18>4SCR5.1039 Houston- TX 77054<x-apple-data-detectors://19/0> T 713-563-2281<tel:713-563-2281>/ 713-563-3301<tel:713-563-3301> F 713-563-3276<tel:713-563-3276> <email obscured><email obscured>> Sent from my iPhone On May 1, 2018, at 9:16 AM, Weis-Garcia, Frances/Sloan Kettering Institute <email obscured><email obscured>>> wrote: Thanks for bringing this to our attention. Sorry I cannot be there ... to much travel going on this spring / early summer. Would love to know how it goes. Frances -----Original Message----- From: "Core Rigor and Reproducibility (CoRRe)" <email obscured><email obscured>>> on behalf of ncfisher <email obscured><email obscured>>> Reply-To: <email obscured><email obscured>>> Date: Tuesday, May 1, 2018 at 8:04 AM To: <email obscured><email obscured>>> Subject: [core rigor and reproducibility (corre)] Rigor and Reproducibility at MADSSCi in June This year, the MADSSCi meeting in Baltimore will be dedicated to Rigor and Reproducibility. http://madssci.abrf.org/ Cores: At the Forefront of Rigor and Reproducibility MAD SSCi 2018 Baltimore, MD - June 18-20, 2018 hosted by the Johns Hopkins University School of Medicine Turner Building Concourse, 720 Rutland Avenue ―― View topic http://list.abrf.org/r/topic/3WaDbHyjr6Itqt7U34559u Leave group <email obscured>?Subject=Unsubscribe
―― View topic http://list.abrf.org/r/topic/3ZhXRGsC24hwHVLCZdamOZ Leave group <email obscured>?Subject=Unsubscribe The information contained in this e-mail message may be privileged, confidential, and/or protected from disclosure. This e-mail message may contain protected health information (PHI); dissemination of PHI should comply with applicable federal and state laws. If you are not the intended recipient, or an authorized representative of the intended recipient, any further review, disclosure, use, dissemination, distribution, or copying of this message or any attachment (or the information contained therein) is strictly prohibited. If you think that you have received this e-mail message in error, please notify the sender by return e-mail and delete all references to it and its contents from your systems.
Thanks for bringing this to our attention.
Sorry I cannot be there ... to much travel going on this spring / early summer.
Would love to know how it goes.
Frances
-----Original Message-----
From: "Core Rigor and Reproducibility (CoRRe)" <email obscured>> on behalf
of ncfisher <email obscured>>
Reply-To: <email obscured>>
Date: Tuesday, May 1, 2018 at 8:04 AM
To: <email obscured>>
Subject: [core rigor and reproducibility (corre)] Rigor and Reproducibility at
MADSSCi in June
This year, the MADSSCi meeting in Baltimore will be dedicated to Rigor and
Reproducibility.
http://madssci.abrf.org/
Cores: At the Forefront of Rigor and Reproducibility
MAD SSCi 2018 Baltimore, MD - June 18-20, 2018
hosted by the Johns Hopkins University School of Medicine
Turner Building Concourse, 720 Rutland Avenue
――
View topic http://list.abrf.org/r/topic/3WaDbHyjr6Itqt7U34559u
Leave group <email obscured>?Subject=Unsubscribe
This year, the MADSSCi meeting in Baltimore will be dedicated to Rigor and Reproducibility. http://madssci.abrf.org/ Cores: At the Forefront of Rigor and Reproducibility MAD SSCi 2018 Baltimore, MD - June 18-20, 2018 hosted by the Johns Hopkins University School of Medicine Turner Building Concourse, 720 Rutland Avenue
Rigor and Reproducibility funding opportunities Funding Opportunities<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.nih.gov_research-2Dtraining_rigor-2Dreproducibility_funding-2Dopportunities&d=DQMFaQ&c=j5oPpO0eBH1iio48DtsedbOBGmuw5jHLjgvtN2r4ehE&r=qT7fPVDkMOYTVUp8gyBQd_AI8ia1-pr3jfWi81PL--8&m=0El9ppwgmic-GASl4LBhhCtQas0XP-rhrEpP0EKJJ9w&s=xboiKpKU6eMcJRIIb7sS7nyhTXJW1jKlsecQESnlhWY&e=> Title: Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplements and Natural Products (Admin Supp)<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PA-2D17-2D447.html&d=DQMFaQ&c=j5oPpO0eBH1iio48DtsedbOBGmuw5jHLjgvtN2r4ehE&r=qT7fPVDkMOYTVUp8gyBQd_AI8ia1-pr3jfWi81PL--8&m=0El9ppwgmic-GASl4LBhhCtQas0XP-rhrEpP0EKJJ9w&s=z4BqCHdnAbpDDbXglpRlGOeCSiYhqm9VmBj3dg-fRz8&e=> ID Number: PA-17-447 Earliest Submission Date: September 15, 2017 Application Due Date: October 13, 2016; June 13, 2017; October 13, 2017; June 13, 2018; October 15, 2018; June 13, 2019 Title: Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R21)<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D16-2D277.html&d=DQMFaQ&c=j5oPpO0eBH1iio48DtsedbOBGmuw5jHLjgvtN2r4ehE&r=qT7fPVDkMOYTVUp8gyBQd_AI8ia1-pr3jfWi81PL--8&m=0El9ppwgmic-GASl4LBhhCtQas0XP-rhrEpP0EKJJ9w&s=1accdIuP7zU_ooMFMC5Rbj-IKsWTk_yaoVh29BAvVak&e=> ID Number: PAR-16-277 Earliest Submission Date: September 13, 2016 Application Due Date: October 13, 2016; June 13, 2017; October 13, 2017; June 13, 2018; October 15, 2018; June 13, 2019 Title: Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01)<https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D16-2D276.html&d=DQMFaQ&c=j5oPpO0eBH1iio48DtsedbOBGmuw5jHLjgvtN2r4ehE&r=qT7fPVDkMOYTVUp8gyBQd_AI8ia1-pr3jfWi81PL--8&m=0El9ppwgmic-GASl4LBhhCtQas0XP-rhrEpP0EKJJ9w&s=pcc1jhdBcBTKuQByHFbgvKYvOBseOwYX5ciauQ_hjSw&e=> ID Number: PAR-16-276 Earliest Submission Date: September 13, 2016 Application Due Date: October 13, 2016; June 13, 2017; October 13, 2017; June 13, 2018; October 15, 2018; June 13, 2019 Title: Tools for Cell Line Identification (SBIR [R43/R44])<https://urldefense.proofpoint.com/v2/url?u=http-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PA-2D16-2D186.html&d=DQMFaQ&c=j5oPpO0eBH1iio48DtsedbOBGmuw5jHLjgvtN2r4ehE&r=qT7fPVDkMOYTVUp8gyBQd_AI8ia1-pr3jfWi81PL--8&m=0El9ppwgmic-GASl4LBhhCtQas0XP-rhrEpP0EKJJ9w&s=SnTbEqvBQX8W0OLogxgKBm7dos1nP1b05KYuxfk05nQ&e=> ID Number: PA-16-186 Earliest Submission Date: August 5, 2016 Application Due Date: Standard dates apply<https://urldefense.proofpoint.com/v2/url?u=http-3A__grants.nih.gov_grants_how-2Dto-2Dapply-2Dapplication-2Dguide_due-2Ddates-2Dand-2Dsubmission-2Dpolicies_standard-2Ddue-2Ddates.htm&d=DQMFaQ&c=j5oPpO0eBH1iio48DtsedbOBGmuw5jHLjgvtN2r4ehE&r=qT7fPVDkMOYTVUp8gyBQd_AI8ia1-pr3jfWi81PL--8&m=0El9ppwgmic-GASl4LBhhCtQas0XP-rhrEpP0EKJJ9w&s=0B4kxj6jTYdyY-g4VrwC7dCgT-Dis0O3bDgqh0dpXnE&e=> Sheenah M. Mische, Ph.D. Sr. Director, Division of Advanced Research Technologies Associate Professor (Research) Department of Pathology NYU Medical Center 550 First Avenue MSB 346 New York, NY 10016 O: 212 263 0859 M: 347 407 2768 http://ocs.med.nyu.edu/
------------------------------------------------------------ This email message, including any attachments, is for the sole use of the intended recipient(s) and may contain information that is proprietary, confidential, and exempt from disclosure under applicable law. Any unauthorized review, use, disclosure, or distribution is prohibited. If you have received this email in error please notify the sender by return email and delete the original message. Please note, the recipient should check this email and any attachments for the presence of viruses. The organization accepts no liability for any damage caused by any virus transmitted by this email. =================================
Hi, I was recently working with an investigator on trouble shooting their ChIP-Seq experiment that apparently had “stopped working”. They insisted nothing had changed. During the discussion they indicated that they had “even purchased a brand new Ab” against the target they were pulling down. After hearing this, some of the horror stories about Ab specificity that were shared at the ABRF 2017 annual meeting suddenly came to mind. I suggested to the investigator that he may want to confirm the specificity and working titer of this “new” antibody. He did a titration experiment and found that the experiment was now “working again” if he used a higher titer of the Ab for the pull down. As noted above, we also discussed Ab validation. I pointed out an article by Natan Blow on page 51 of the August Issue of BioTechniques. He noted that “many articles have been written about the problem of antibody validation, but far fewer have focused on the solutions. In the article, there is reference to a scoring system that was develop by the GBSI that could be used to evaluate Abs. There was also a reference to David Rimm (2010) that illustrated a proposed validation flowchart. I shared these validation workflows with the investigator and he indicated that he would not likely follow through the validation workflows suggested by this article. He expects the provider of the Ab to have already done the validation. I am curious to know if other cores have had similar experiences when working with investigators who are using Abs to prepare samples for use in your facility. Minimally, what are you advising your users to do when working with Abs?
Thanks, Kevin -- Kevin L. Knudtson, Ph.D. University of Iowa Director, IIHG Genomics Division 323 EMRB Iowa City, IA 52242 TEL: 319-335-7251 FAX: 319-335-6737 E-mail: <email obscured><email obscured>>
Sorry, this post is hidden. The reason that Alexy Mikhailichenko gave for hiding the post is as follows:
Test
If you think you should be able to see the post email support and we will see what we can do to help.
Nancy, Under Kevin's leadership CoRRe is pulling a manuscript together to publish in JBT. I am sure we will post it here, as well as the ABRF Newsletter once it is online. Was there something in particular you were interested in knowing from what was presented on the poster at ABRF2017?
Frances
Dear All, This is a test of the response function Henriette CCoRRe member University of Michigan
Dear CoRRe Discussion Forum Participants, Paula Turpen shared a new term that she and I were unfamiliar with until she heard it on NPR ... the “R” Index or Replicability Index. Have any of you heard about it? Click this link for a podcast of the interview with interview with Ulrich Schimmack on the NPR radio show “on the media” <http://www.npr.org/podcasts/452538775/on-the-media> where Paula first heard about it. Uli’s session comes in at the 10:45 minute mark, and lasts for 10 minutes. You can also check out their blog on this topic <https://replicationindex.wordpress.com/>. Thought on the "new" R Index?
Frances